NCT00648323View on ClinicalTrials.gov

Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

January 31, 2005

Conditions
Prostate
Interventions
DRUG

Doxazosin mysylate GITS

Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.

Trial Locations (4)

813

Pfizer Investigational Site, Kaohsiung City

Unknown

Pfizer Investigational Site, Taichung

Pfizer Investigational Site, Taipei

Pfizer Investigational Site, Taoyuan District

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00648323 - Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement | Biotech Hunter | Biotech Hunter